HRP20131116T1 - Derivati kinolina kao antibakterijska sredstva - Google Patents
Derivati kinolina kao antibakterijska sredstva Download PDFInfo
- Publication number
- HRP20131116T1 HRP20131116T1 HRP20131116TT HRP20131116T HRP20131116T1 HR P20131116 T1 HRP20131116 T1 HR P20131116T1 HR P20131116T T HRP20131116T T HR P20131116TT HR P20131116 T HRP20131116 T HR P20131116T HR P20131116 T1 HRP20131116 T1 HR P20131116T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound
- het
- use according
- bacterial infection
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title claims 3
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 208000035143 Bacterial infection Diseases 0.000 claims 15
- 208000022362 bacterial infectious disease Diseases 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 239000003242 anti bacterial agent Substances 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 206010062207 Mycobacterial infection Diseases 0.000 claims 5
- -1 cyano, hydroxy Chemical group 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 239000003926 antimycobacterial agent Substances 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 2
- 125000000815 N-oxide group Chemical group 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 229960003085 meticillin Drugs 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (25)
1. Uporaba spoja za proizvodnju medikamenta za liječenje bakterijske infekcije, te je navedeni spoj, spoj sa Formulom (Ia) i (Ib)
[image]
[image]
njihova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njihov kvaternarni amin, njihov stereokemijski izomerni oblik, njihov tautomerni oblik ili njihov N-oksidni oblik, naznačen time da
R1 je vodik, halo, haloalkil, cijano, hidroksi, Ar, Het, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil ;
p je cijeli broj jednak 1, 2 ili 3;
R2 je vodik; alkil; hidroksi; merkapto; alkiloksi proizvoljno supstituiran sa amino ili mono ili di(alkil)amino ili radikal sa formulom
[image]
pri čemu Z je CH2, CH-R10, O, S, N-R10 i t je cijeli broj jednak 1 ili 2 i isprekidana linija predstavlja proizvoljnu vezu; alkiloksialkiloksi; alkiltio; mono ili di(alkil)amino pri čemu alkil može biti proizvoljno supstituiran sa jednim ili dva supstituenta koji su svaki neovisno odabrani od alkiloksi ili Ar ili Het ili morfolinila ili 2-oksopirolidinila; Ar; Het ili radikala sa formulom
[image]
pri čemu Z je CH2, CH-R10, O, S, N-R10; t je cijeli broj jednak 1 ili 2; i isprekidana linija predstavlja proizvoljnu vezu;
R3 je alkil, Ar, Ar-alkil, Het ili Het-alkil;
q je cijeli broj jednak nula, 1, 2, 3 ili 4;
X je izravna veza ili CH2;
R4 i R5 su svaki neovisno vodik, alkil ili benzil; ili
R4 i R5 zajedno i uključujući N na koji su spojeni mogu tvoriti radikal koji je odabran iz skupine koja sadrži imidazolil, triazolil, piperidinil, piperazinil i tiomorfolinil;
R6 je vodik ili radikal sa formulom
[image]
pri čemu s je cijeli broj jednak nula, 1, 2, 3 ili 4; r je cijeli broj jednak 1, 2, 3, 4 ili 5; i R11 je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili dva susjedna R11 radikala mogu biti uzeti da zajedno sa fenilnim prstenom na koji su spojeni tvore naftil;
R7 je vodik, alkil, Ar ili Het;
R8 je vodik ili alkil;
R9 je okso; ili
R8 i R9 zajedno tvore radikal -CH=CH-N=;
R10 je vodik, alkil, hidroksil, aminokarbonil, mono-ili di(alkil)aminokarbonil, Ar, Het, alkil supstituiran sa jednim ili dva Het, alkil supstituiran sa jednim ili dva Ar, Het-C(=O)-, Ar-C(=O)-;
alkil je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma spojenih na ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; pri čemu svaki atom ugljika proizvoljno može biti supstituiran sa hidroksi, alkiloksi ili okso;
Ar je homocikal odabran iz skupine koja sadrži fenil, naftil, acenaftil, tetrahidronaftil, svaki proizvoljno supstituiran sa 1, 2 ili 3 supstituenta, te je svaki supstituent neovisno odabran iz skupine koja sadrži hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkil, haloalkil, alkiloksi, haloalkiloksi, karboksil, alkiloksikarbonil, alkilkarbonil, aminokarbonil, morfolinil i mono- ili dialkilaminokarbonil;
Het je monociklički heterocikal odabran iz skupine koja sadrži N-fenoksipiperidinil, piperidinil, pirolil, pirazolil, imidazolil, furanil, tienil, oksazolil, izoksazolil, tiazolil, izotiazolil, triazolil, piridinil, pirimidinil, pirazinil i piridazinil; ili biciklički heterocikal odabran iz skupine koja sadrži kinolinil, izokinolinil, 1,2,3,4-tetrahidroizokinolinil, kinoksalinil, indolil, indazolil, benzimidazolil, benzoksazolil, benzizoksazolil, benzotiazolil, benzizotiazolil, benzofuranil, benzotienil, 2,3-dihidrobenzo[1,4]dioksinil ili benzo[1,3]dioksolil; svaki monociklički i biciklički heterocikal može biti proizvoljno supstituiran na atomu ugljika sa 1, 2 ili 3 supstituenta, te je svaki supstituent neovisno odabran iz skupine koja sadrži halo, hidroksi, alkil ili alkiloksi;
halo je supstituent odabran iz skupine koja sadrži fluoro, kloro, bromo i jodo i
haloalkil je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma spojenih na ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; pri čemu su jedan ili više ugljikovih atoma supstituirani sa jednim ili više halo atoma; pri čemu radikal
[image]
također može biti postavljen na položaj 4 u kinolinskom prstenu; te uz uvjet da bakterijska infekcija nije mikobakterijska infekcija.
2. Uporaba prema zahtjevu 1 naznačena time da R1 je vodik, halo ili Het.
3. Uporaba prema zahtjevu 2 naznačena time da R1 je halo.
4. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da p je jednak 1.
5. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R2 je alkiloksi; Het; Ar mono ili di(alkil)amino pri čemu alkil može biti proizvoljno supstituiran sa jednim ili dva Ar supstituenta; radikal sa formulom
[image]
pri čemu Z je N-R10 ; t je cijeli broj jednak 2; alkiloksi supstituiran sa amino ili mono ili di(alkil)amino
ili radikal sa formulom
[image]
pri čemu Z je CH2 i t je cijeli broj jednak 2.
6. Uporaba prema zahtjevu 5 naznačena time da R2 je alkiloksi.
7. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R3 je naftil, fenil ili Het, svaki proizvoljno supstituiran sa 1 ili 2 supstituenta.
8. Uporaba prema zahtjevu 7 naznačena time da R3 je naftil, fenil, 3,5-dihalofenil, tienil, furanil ili benzofuranil.
9. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da q je jednak 1.
10. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R4 i R5 svaki neovisno su alkil.
11. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R6 je benzil ili fenil.
12. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R7 je vodik.
13. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da X je izravna veza.
14. Uporaba prema bilo kojem zahtjevu od 1 do 12 naznačena time da X je CH2.
15. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da spoj je spoj prema Formuli (Ia).
16. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da bakterijska infekcija je infekcija sa gram-pozitivnom bakterijom.
17. Kombinacija (a) spoja sa Formulom (Ia) ili (Ib) kako je definirano u bilo kojem zahtjevu od 1 do 15, i (b) jednog ili više drugih antibakterijskih sredstava uz uvjet da jedno ili više drugih antibakterijskih sredstava nisu antimikobakterijska sredstva, naznačena time da je kombinacija za uporabu kod liječenja bakterijske infekcije uz uvjet da bakterijska infekcija nije mikobakterijska infekcija.
18. Farmaceutski pripravak koji sadrži farmaceutski prihvatljiv nosač, te kao aktivnu tvar, terapeutski učinkovitu količinu (a) spoja sa Formulom (Ia) ili (Ib) kako je definirano u bilo kojem zahtjevu od 1 do 15, i (b) jedno ili više drugih antibakterijskih sredstava uz uvjet da jedno ili više drugih antibakterijskih sredstava nisu antimikobakterijska sredstva, naznačena time da je kombinacija za uporabu kod liječenja bakterijske infekcije uz uvjet da bakterijska infekcija nije mikobakterijska infekcija.
19. Spoj kako je definirano u bilo kojem zahtjevu od 1 do 15, naznačen time da je za uporabu kod liječenja bakterijske infekcije uz uvjet da bakterijska infekcija nije mikobakterijska infekcija.
20. Proizvod koji sadrži (a) spoj sa Formulom (Ia) ili (Ib) kako je definirano u bilo kojem zahtjevu od 1 do 15, i (b) jedno ili više drugih antibakterijskih sredstava uz uvjet da jedno ili više drugih antibakterijskih sredstava nisu antimikobakterijska sredstva, kao kombiniranog pripravka za istovremenu, odvojenu ili uzastopnu uporabu kod liječenja bakterijske infekcije uz uvjet da bakterijska infekcija nije mikobakterijska infekcija.
21. Spoj naznačen time da je odabran od
[image]
ili
[image]
njihova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njihov kvaternarni amin, njihov stereokemijski izomerni oblik, njihov tautomerni oblik ili njihov N-oksidni oblik.
22. Uporaba prema bilo kojem zahtjevu od 1 do 16, kombinacije prema zahtjevu 17, pripravka prema zahtjevu 18, spoja prema zahtjevu 19 ili proizvoda prema zahtjevu 20, naznačena time da bakterijska infekcija je infekcija sa bakterijom Staphilococci, Enterococci ili Streptococci.
23. Uporaba, kombinacije, pripravka, spoja ili proizvoda prema zahtjevu 22, naznačena time da bakterijska infekcija je infekcija sa meticilin rezistentnom Staphilococcus aureus (MRSA), meticilin rezistentnim koagulaza-negativnim stafilokokom (MRCNS), penicilin rezistentnom Streptococcus pneumoniae ili višestruko rezistentnim Enterococcus faecium.
24. Uporaba, kombinacije, pripravka, spoja ili proizvoda prema zahtjevu 23, naznačena time da bakterijska infekcija je infekcija sa Staphilococcus aureus ili Streptococcus pneumoniae.
25. Uporaba, kombinacije, pripravka, spoja ili proizvoda prema zahtjevu 24, naznačena time da bakterijska infekcija je infekcija sa Staphilococcus aureus (MRSA).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107159 | 2005-08-03 | ||
| PCT/EP2006/064856 WO2007014940A2 (en) | 2005-08-03 | 2006-07-31 | Quinoline derivatives as antibacterical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131116T1 true HRP20131116T1 (hr) | 2013-12-20 |
Family
ID=35768940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131116TT HRP20131116T1 (hr) | 2005-08-03 | 2013-11-22 | Derivati kinolina kao antibakterijska sredstva |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8017606B2 (hr) |
| EP (1) | EP1912647B1 (hr) |
| JP (1) | JP5410753B2 (hr) |
| KR (1) | KR101337237B1 (hr) |
| CN (1) | CN101277695B (hr) |
| AR (1) | AR054889A1 (hr) |
| AU (1) | AU2006274879B2 (hr) |
| BR (1) | BRPI0614524B8 (hr) |
| CA (1) | CA2615901C (hr) |
| CY (1) | CY1114908T1 (hr) |
| DK (1) | DK1912647T3 (hr) |
| EA (1) | EA014832B1 (hr) |
| ES (1) | ES2437575T3 (hr) |
| HK (1) | HK1124233A1 (hr) |
| HR (1) | HRP20131116T1 (hr) |
| IL (1) | IL189141A (hr) |
| JO (1) | JO2952B1 (hr) |
| MX (1) | MX2008001602A (hr) |
| MY (1) | MY148241A (hr) |
| NO (1) | NO341247B1 (hr) |
| NZ (1) | NZ565283A (hr) |
| PL (1) | PL1912647T3 (hr) |
| PT (1) | PT1912647E (hr) |
| RS (1) | RS53065B (hr) |
| SI (1) | SI1912647T1 (hr) |
| TW (1) | TWI381839B (hr) |
| UA (1) | UA95916C2 (hr) |
| WO (1) | WO2007014940A2 (hr) |
| ZA (1) | ZA200801108B (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01065B (me) * | 2004-01-23 | 2012-10-20 | Janssen Pharmaceutica Nv | Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora |
| JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| US20110059948A1 (en) * | 2008-01-14 | 2011-03-10 | Jyoti Chattopadhyaya | Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents |
| JP5246715B2 (ja) | 2009-01-27 | 2013-07-24 | 独立行政法人科学技術振興機構 | 蛋白質架橋阻害剤およびその用途 |
| WO2010144102A1 (en) * | 2009-06-09 | 2010-12-16 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command | Pentafluorosulfanyl analogs of mefloquine |
| CA2869718C (en) | 2012-04-27 | 2021-05-11 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| PL2841426T3 (pl) | 2012-04-27 | 2017-03-31 | Janssen Pharmaceutica N.V. | Przeciwbakteryjne pochodne chinoliny |
| CN105209453B (zh) | 2012-10-16 | 2017-06-20 | 詹森药业有限公司 | ROR‑γ‑T的亚甲基连接的喹啉基调节剂 |
| ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
| CA2888485C (en) | 2012-10-16 | 2021-01-26 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror.gamma.t |
| US9642858B2 (en) | 2012-10-30 | 2017-05-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of resazurin, or analogs thereof, for antibacterial therapy |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| AU2013403336A1 (en) | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORyt |
| US9346782B2 (en) | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9624225B2 (en) | 2013-10-15 | 2017-04-18 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORγt |
| GB201904796D0 (en) * | 2019-04-04 | 2019-05-22 | Univ Sheffield | Antimicrobial agent |
| AR121683A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
| AR121682A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317491D0 (en) | 1993-08-23 | 1993-10-06 | Fujisawa Pharmaceutical Co | New compound and a process for preparation thereof |
| US6376670B1 (en) * | 1997-06-19 | 2002-04-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| GB9914486D0 (en) * | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
| GB9917408D0 (en) * | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
| GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
| ES2395237T3 (es) | 2002-07-25 | 2013-02-11 | Janssen Pharmaceutica N.V. | Derivados de quinolina como compuestos intermedios para inhibidores micobacterianos |
| CN101817815A (zh) * | 2002-10-10 | 2010-09-01 | 莫弗凯姆联合化学股份公司 | 具有杀菌活性的化合物 |
| DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| MXPA06005686A (es) * | 2003-11-20 | 2006-08-17 | Janssen Pharmaceutica Nv | 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa. |
| SG151249A1 (en) * | 2003-12-05 | 2009-04-30 | Janssen Pharmaceutica Nv | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| ME01065B (me) * | 2004-01-23 | 2012-10-20 | Janssen Pharmaceutica Nv | Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora |
| JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
-
2006
- 2006-07-18 JO JO2006233A patent/JO2952B1/en active
- 2006-07-31 EP EP06778081.7A patent/EP1912647B1/en active Active
- 2006-07-31 SI SI200631705T patent/SI1912647T1/sl unknown
- 2006-07-31 PL PL06778081T patent/PL1912647T3/pl unknown
- 2006-07-31 AU AU2006274879A patent/AU2006274879B2/en not_active Ceased
- 2006-07-31 RS RS20130539A patent/RS53065B/en unknown
- 2006-07-31 ES ES06778081.7T patent/ES2437575T3/es active Active
- 2006-07-31 BR BRPI0614524A patent/BRPI0614524B8/pt not_active IP Right Cessation
- 2006-07-31 WO PCT/EP2006/064856 patent/WO2007014940A2/en active Application Filing
- 2006-07-31 DK DK06778081.7T patent/DK1912647T3/da active
- 2006-07-31 PT PT67780817T patent/PT1912647E/pt unknown
- 2006-07-31 NZ NZ565283A patent/NZ565283A/en not_active IP Right Cessation
- 2006-07-31 EA EA200800501A patent/EA014832B1/ru unknown
- 2006-07-31 US US11/997,182 patent/US8017606B2/en active Active
- 2006-07-31 MX MX2008001602A patent/MX2008001602A/es active IP Right Grant
- 2006-07-31 KR KR1020087005066A patent/KR101337237B1/ko active IP Right Grant
- 2006-07-31 UA UAA200801433A patent/UA95916C2/ru unknown
- 2006-07-31 JP JP2008524508A patent/JP5410753B2/ja not_active Expired - Fee Related
- 2006-07-31 CN CN200680036637XA patent/CN101277695B/zh not_active Expired - Fee Related
- 2006-07-31 CA CA2615901A patent/CA2615901C/en active Active
- 2006-08-01 MY MYPI20063726A patent/MY148241A/en unknown
- 2006-08-02 AR ARP060103371A patent/AR054889A1/es not_active Application Discontinuation
- 2006-08-02 TW TW095128223A patent/TWI381839B/zh active
-
2008
- 2008-01-31 IL IL189141A patent/IL189141A/en active IP Right Grant
- 2008-02-01 ZA ZA200801108A patent/ZA200801108B/xx unknown
- 2008-02-25 NO NO20080955A patent/NO341247B1/no not_active IP Right Cessation
-
2009
- 2009-02-05 HK HK09101044.5A patent/HK1124233A1/xx not_active IP Right Cessation
-
2013
- 2013-11-22 HR HRP20131116TT patent/HRP20131116T1/hr unknown
- 2013-12-11 CY CY20131101116T patent/CY1114908T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131116T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2009503024A5 (hr) | ||
| HRP20140206T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| HRP20170044T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2009503025A5 (hr) | ||
| HRP20120910T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20110392T1 (hr) | Derivati kinolina za liječenje latentne tuberkuloze | |
| HRP20161704T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20090673T1 (hr) | Derivati kvinolina i njihova uporaba kao mikobakterijskih inhibitora | |
| HRP20151111T1 (hr) | Kinuklidinski spojevi kao ligandi nikotinskog acetilkolin alfa-7 receptora | |
| HRP20120912T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20210484T1 (hr) | Antimikrobna sredstva koja se temelje na imidazolu | |
| HRP20201023T1 (hr) | Dioksilan analozi uridina za liječenje raka | |
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| RS52808B (en) | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | |
| CA2478229A1 (en) | Pyridinoylpiperidines as 5-ht1f agonists | |
| HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
| HRP20141108T1 (hr) | Antagonisti piperidinon karboksamid azaindan cgrp receptora | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| HRP20150139T1 (hr) | Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina | |
| HRP20100428T1 (hr) | Antibakterijski derivati kvinolina | |
| JP2008546824A5 (hr) | ||
| HRP20151308T1 (hr) | Antibakterijski derivati kinolina | |
| JP2010511667A5 (hr) |